Is a 58 gene panel that includes assessment of non-coding variants.
In addition, it also includes the maternally inherited mitochondrial genome. Is ideal for patients with a clinical suspicion of dementia.Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous group of non-Alzheimer dementias characterized by selective, progressive cortical atrophy involving the frontal or temporal lobes. FTD is substantially less common than Alzheimer’s disease, with estimates of population prevalence ranging from 4-5 per 100,000 before age 65. Age of onset is typically in the sixth decade of life. However, it may begin as early 30 or as late as the ninth decade. Approximately 20-50% of individuals with FTD have an affected first degree relative. FTD has a substantial genetic component, with an autosomal dominant or X-linked inheritance pattern. It is estimated that 10% of patients with FTD have a disease causing mutation in a single gene. The APOE E4 haplotype confers a significant risk for Alzheimer’s disease related dementia, especially in homozygous state. Therefore, this haplotype is reported from this panel, if detected in homozygous state.
Is a 58 gene panel that includes assessment of non-coding variants.
In addition, it also includes the maternally inherited mitochondrial genome. Is ideal for patients with a clinical suspicion of dementia.Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous group of non-Alzheimer dementias characterized by selective, progressive cortical atrophy involving the frontal or temporal lobes. FTD is substantially less common than Alzheimer’s disease, with estimates of population prevalence ranging from 4-5 per 100,000 before age 65. Age of onset is typically in the sixth decade of life. However, it may begin as early 30 or as late as the ninth decade. Approximately 20-50% of individuals with FTD have an affected first degree relative. FTD has a substantial genetic component, with an autosomal dominant or X-linked inheritance pattern. It is estimated that 10% of patients with FTD have a disease causing mutation in a single gene. The APOE E4 haplotype confers a significant risk for Alzheimer’s disease related dementia, especially in homozygous state. Therefore, this haplotype is reported from this panel, if detected in homozygous state.
Test Duration: N/A
Home Sample Collection: No
Category: Cognition & Neurology Testing
Lab: N/A
Price: $0.00
Test Features
Genetic factors can contribute to a wide range of neurological and neurodevelopmental conditions. Our Neurological Genetics Panel helps identify inherited genetic variants associated with dementia, movement disorders, neurodevelopmental conditions, and other neurological diseases, providing valuable information for diagnosis, risk assessment, family planning, and clinical management.
Our comprehensive testing panels may include genetic causes associated with: ●Alzheimer's Disease and other forms of dementia ●Frontotemporal Dementia (FTD) ●Parkinson's Disease ●Huntington's Disease ●Amyotrophic Lateral Sclerosis (ALS) ●Hereditary Ataxias ●Epilepsy and seizure disorders ●Autism Spectrum Disorder (ASD) ●Intellectual and developmental disabilities ●Other inherited neurological conditions
●Individuals with symptoms suggestive of a neurological disorder ●Those with a family history of dementia, Parkinson's disease, or other neurological conditions ●Families seeking to understand inherited risks ●Individuals considering predictive or presymptomatic testing ●Parents investigating potential genetic causes of neurodevelopmental conditions
●Supports accurate diagnosis and clinical management ●Identifies inherited risk factors ●Assists with family planning decisions ●Helps inform treatment and surveillance strategies ●Provides clarity for patients and their families
Using a blood or saliva sample, advanced genetic sequencing technology analyses genes associated with neurological and neurodevelopmental conditions. Results are interpreted by experienced specialists and may be accompanied by genetic counselling to help you understand the findings and available options. Understanding your genetics can provide valuable answers, guide healthcare decisions, and help families plan for the future with greater confidence.
